![Anand Patel: Does JAK2 VAF reduction in PV/ET impact outcomes in rux-treated patients?](https://oncodaily.com/pub/uploads/2024/06/Anand-Patel-real-e1693521880399-1280x1075-1.webp)
Photo from Anand Patel/X
Jul 2, 2024, 13:10
Anand Patel: Does JAK2 VAF reduction in PV/ET impact outcomes in rux-treated patients?
Anand Patel, Assistant Professor and Director of the Inpatient Leukemia Service at the University of Chicago, shared on X/Twitter:
“Does JAK2 VAF reduction in PV/ET impact outcomes in rux-treated patients?
Pic 1 – MF-free survival in patients treated with rux on PV or ET trials:
Pic 2 – events on MAJIC-PV trial.”
Source: Anand Patel/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023